Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | IDH2 | P48735 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | TGM1 | P22735 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27196781 | 0.82 | SYK (0.45) | IDH1IDH2GPR119RORCF13A1 | |
| SCHEMBL229653 | 0.80 | KMT2A (0.47) | GPR119RORCMEN1KMT2A | |
| SCHEMBL26081084 | 0.79 | MGLL (0.46) | IDH1IDH2GPR119TACR1 | |
| SCHEMBL5705772 | 0.79 | KMT2A (0.60) | GPR119MEN1KMT2A | |
| SCHEMBL16632062 | 0.79 | STS (0.51) | GPR119KMT2A | |
| SCHEMBL15565611 | 0.78 | KDM4E (0.50) | GPR119RORCTACR1MEN1KMT2A | |
| SCHEMBL26081087 | 0.78 | GPR119 (0.41) | IDH1IDH2GPR119F13A1TGM2 | |
| SCHEMBL21605904 | 0.78 | USP30 (0.46) | HDAC4GPR119TACR1MEN1KMT2A | |
| SCHEMBL30328592 | 0.78 | GPR119 (0.50) | GPR119MEN1KMT2A | |
| SCHEMBL26081185 | 0.77 | CNR2 (0.42) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | IDH1 887/4885IDH2 631/4885HDAC4 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.